Cox Models Survival Analysis Based on Breast Cancer Treatments

Alireza Abadi; Parvin Yavari; Monireh Dehghani-Arani; Hamid Alavi-Majd; Erfan Ghasemi; Farzaneh Amanpour; Chris Bajdik

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Copyright

Cox Models Survival Analysis Based on Breast Cancer Treatments

Authors:

Alireza Abadi¹,

Parvin Yavari^1,*,

Monireh Dehghani-Arani²,

Hamid Alavi-Majd²,

Erfan Ghasemi²,

Farzaneh Amanpour²,

Chris Bajdik³

1Dept. of Health and Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Dept. of Biostatistics, Paramedical Sciences Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3Cancer Control Research Program, BC Cancer Agency, Vancouver, British Columbia, Canada

International Journal of Cancer Management:Vol. 7, issue 3; e80539

Published online:Sep 30, 2014

Article type:Research Article

Received:Feb 16, 2014

Accepted:May 30, 2014

How to Cite:Alireza AbadiParvin YavariMonireh Dehghani-AraniHamid Alavi-MajdErfan GhasemiFarzaneh AmanpourChris Bajdiket al.Cox Models Survival Analysis Based on Breast Cancer Treatments.7(3):e80539.

Abstract

Background: The aim of this study is to evaluate the association between different treatments and survival time of breast cancer patients using either standard Cox model or stratified Cox model.

Methods: The study was conducted on 15830 women diagnosed with breast cancer in British Columbia, Canada. They were divided into eight groups according to patients’ ages and stage of disease Either Cox’s PH model or stratified Cox model was fitted to each group according to the PH assumption and tested using Schoenfeld residuals.

Results: The data show that in the group of patients under age 50 years old and over age 50 with stage Ι cancer, the highest hazard was related to radiotherapy (HR= 3.15, CI: 1.85-5.35) and chemotherapy (HR= 3, CI: 2.29- 3.93) respectively. For both groups of patients with stage ΙΙ cancer, the highest risk was related to radiotherapy (HR=3.02, CI: 2.26-4.03) (HR=2.16, CI:1.85-2.52). For both groups of patients with stage III cancer, the highest risk was for surgery (HR=0.49, CI: 0.33-0.73), (HR=0.45, CI: 0.36-0.57). For patients of age 50 years or less with stage IV cancer, none of the treatments were statistically significant. In group of patients over age 50 years old with stage ΙV cancer, the highest hazard was related to surgery (HR=0.64, CI: 0.53-0.78).

Conclusion: The results of this study show that for patients with stage I and II breast cancer, radiotherapy and chemotherapy had the highest hazard; for patients with stage III and IV breast cancer, the highest hazard was associated with treatment surgery.

Keywords

Fulltext

Full text is available in PDF.

comments